Early observations and pilot data that first suggested a new direction
The TICORA study in 2004 established the treat-to-target paradigm for rheumatoid arthritis. Among 111 patients with active RA for less than 5 years, intensive management with monthly disease activity monitoring and protocolized treatment escalation achieved remission in 65% versus 16% with routine care (p<0.0001). The mean DAS improvement was -3.5 versus -1.9 (p<0.0001). This demonstrated that the strategy of tight control mattered as much as the specific drugs used, fundamentally reshaping RA management principles.
Landmark RCTs and pivotal trials that established the evidence base
The BeSt trial compared four treatment strategies in 508 patients with early RA: sequential monotherapy, step-up combination, initial combination with high-dose prednisone, or initial combination with infliximab. Initial combination therapy (groups 3 and 4) produced earlier functional improvement and less radiographic damage at 1 year than sequential or step-up approaches, demonstrating the superiority of early aggressive combination therapy. The 10-year follow-up showed sustained benefits of initial combination approaches, embedding the principle of early, aggressive treatment in RA management.
Follow-up studies, subgroup analyses, and real-world validation
The ORAL Surveillance trial introduced a critical safety dimension to treatment strategy. This FDA-mandated trial randomized 4,362 RA patients aged ≥50 with cardiovascular risk factors to tofacitinib (JAK inhibitor) 5 mg or 10 mg versus a TNF inhibitor. Tofacitinib failed to demonstrate noninferiority for MACE (HR 1.33; 95% CI 0.91-1.94) and showed significantly increased cancer risk (HR 1.48; 95% CI 1.04-2.09). This trial reshaped JAK inhibitor positioning, leading to FDA label changes and EMA restrictions limiting JAK inhibitors to patients who have failed biologic DMARDs.
Integration into clinical practice guidelines and recommendations
ACR/EULAR guidelines embed the treat-to-target principle with methotrexate as first-line DMARD, escalation to biologic or targeted synthetic DMARDs if the treatment target (remission or low disease activity) is not achieved within 3-6 months, and safety-stratified selection of advanced therapies. Post-ORAL Surveillance, JAK inhibitors are generally positioned after failure of biologic DMARDs, particularly in patients over 65 or with cardiovascular risk factors.
EULAR
Treat-to-target with methotrexate first-line; escalation to biologics or targeted synthetics if target not met; JAK inhibitors after biologic failure given safety signals
ACR
Methotrexate first-line; biologic or targeted DMARD if inadequate response; strong recommendation for treat-to-target strategy
Now
Current standard of care and ongoing research directions
RA treatment strategy integrates three principles: (1) tight-control treat-to-target with regular disease activity monitoring; (2) early aggressive therapy, including combination approaches for high-risk patients; and (3) safety-informed drug selection, particularly the positioning of JAK inhibitors after ORAL Surveillance. The therapeutic landscape includes multiple biologic classes and targeted synthetic DMARDs, enabling personalized treatment. Biomarker-guided therapy selection and drug-free remission remain active research areas.
Treat-to-target involves setting a specific disease activity target (remission or low disease activity), monitoring with validated composite measures every 1-3 months, and systematically escalating therapy if the target is not met within 3-6 months. The TICORA study showed this approach achieved 65% remission vs 16% with routine care.
Why are JAK inhibitors restricted after the ORAL Surveillance trial?+
ORAL Surveillance (4,362 patients) showed tofacitinib did not meet noninferiority vs TNF inhibitors for cardiovascular events (HR 1.33) and was associated with increased cancer risk (HR 1.48; 95% CI 1.04-2.09). Regulatory agencies now restrict JAK inhibitors to patients who have failed biologic DMARDs, particularly those over 65 or with cardiovascular risk factors.
